0001209191-21-021550.txt : 20210317 0001209191-21-021550.hdr.sgml : 20210317 20210317190052 ACCESSION NUMBER: 0001209191-21-021550 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210315 FILED AS OF DATE: 20210317 DATE AS OF CHANGE: 20210317 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GRIFFIN MICHELLE RENEE CENTRAL INDEX KEY: 0001229765 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 21752308 MAIL ADDRESS: STREET 1: 19723 NE 65TH LANE CITY: KIRKLAND STATE: WA ZIP: 98033 FORMER NAME: FORMER CONFORMED NAME: BURRIS MICHELLE DATE OF NAME CHANGE: 20030429 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-15 0 0001478320 Adaptive Biotechnologies Corp ADPT 0001229765 GRIFFIN MICHELLE RENEE C/O ADAPTIVE BIOTECHNOLOGIES CORP. SUITE 200 SEATTLE WA 98102 1 0 0 0 Common Stock 2021-03-15 4 M 0 4500 7.80 A 6004 D Common Stock 2021-03-15 4 S 0 891 41.17 D 5113 D Common Stock 2021-03-15 4 S 0 3609 41.89 D 1504 D Common Stock 2021-03-16 4 M 0 1500 7.80 A 3004 D Common Stock 2021-03-16 4 S 0 1500 47.00 D 1504 D Stock Option (Right to Buy) 7.80 2021-03-15 4 M 0 4500 0.00 D 2029-04-23 Common Stock 4500 84500 D Stock Option (Right to Buy) 7.80 2021-03-16 4 M 0 1500 0.00 D 2029-04-23 Common Stock 1500 83000 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $40.51 to 41.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.51 to 42.23, inclusive. The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. /s/ Michelle Griffin by Eric Billings, attorney-in-fact 2021-03-17